October 29th, 2026Joint Ventures: Gout Management Gaps Persist Despite Effective Therapies, GuidelinesBuss and Arnolds discuss underscore persistent gaps between gout guideline recommendations and real-world practice.Read more
November 17th, 2026Secukinumab Receives FDA Approval for Polymyalgia RheumaticaSecukinumab 150 mg doubled week-52 sustained remission vs placebo in REPLENISH, making it the first anti-IL-17 biologic approved for PMR.Read more
November 11th, 2026Afimetoran Meets Primary End Point Across 3 Doses in Phase 2 SLE TrialAfimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.Read more
November 10th, 2026Oral Icotrokinra Meets Primary End Point in Phase 3 Psoriatic Arthritis TrialThe 200-mg dose improved ACR20 response vs placebo at week 16 in biologic-naïve patients, while the 400-mg dose added no benefit.Read more
November 10th, 2026IgG4-RD Treatment Guidelines Favor Steroid Sparing, B-cell TherapiesAn international IgG4ward! Foundation panel issued 28 treatment statements for IgG4-related diseases, with consensus reached on 22.Read more
November 10th, 2026Nerandomilast Trends Toward Benefit in Myositis-Associated ILD SubgroupIn 33 patients with myositis-associated ILD from FIBRONEER-ILD, nerandomilast numerically slowed FVC decline and lowered progression risk.Read more
November 10th, 2026Vagus Nerve Stimulation Shows Sustained RA Responses at 24 MonthsRESET-RA 24-month data show sustained clinical responses with vagus nerve stimulation in patients with treatment-experienced RA.Read more
November 10th, 2026Sarilumab Tops Methotrexate for Glucocorticoid Discontinuation in PMRIn a matched claims analysis, 94% of patients with PMR initiating sarilumab discontinued glucocorticoids by 12 months vs 78% initiating methotrexate.Read more